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Abstract L-Arrestins mediate agonist dependent desensitization
of G protein-coupled receptors. Somatic TSH receptor mutations
were identified in the majority of hot thyroid nodules. When
transiently overexpressed in COS 7 cells these mutations resulted
in constitutive activation of the cAMP pathway. However, the in
vivo mechanisms and the in vivo desensitization of these TSH
receptor mutations are unknown. Moreover, constitutively
activated L-adrenergic receptors are known to be constitutively
desensitized. Therefore, we investigated the expression of L-
arrestins in toxic thyroid nodules (TTNs) with and without
somatic TSH receptor mutation and in cold thyroid nodules
(CTNs) by Western blotting and ELISA. Expression of L-
arrestin 2 was increased in all TTNs while L-arrestin 2
expression was decreased in CTNs compared to their corre-
sponding surrounding tissue. The mean L-arrestin 1 expression
was unchanged in the cytosol of TTNs, in membranes and cytosol
of CTNs and decreased in the membranes of TTNs compared to
their surrounding tissue. Transient coexpression of L-arrestins 1
or 2 with the TSH receptor in HEK 293 cells and subsequent
determination of cAMP showed that in vitro both L-arrestins
interact with the TSH receptor and are able to desensitize the
receptor. The increased L-arrestin 2 expression in TTNs and the
desensitization of the TSH receptor by L-arrestin 2 in vitro
suggest that the L-arrestin 2 expression is cAMP dependent and
that L-arrestin 2 very likely desensitizes the constitutively
activated TSH receptor in toxic thyroid nodules. ß 2000 Fed-
eration of European Biochemical Societies. Published by Else-
vier Science B.V. All rights reserved.
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1. Introduction
Binding of L-arrestins to receptors phosphorylated by G
protein-coupled receptor kinases (GRK’s) quenches activation
of G proteins and targets the receptors to clathrin-coated pits
for internalization [1^8]. L-Arrestins therefore play an impor-
tant role in agonist dependent desensitization of G protein-
coupled receptors. L-Arrestin 1 mRNA and protein expression
and its function as a negative regulator of TSH receptor
stimulated cAMP has been reported for FRTL 5 cells [9,10].
TSH receptor internalization and recycling is mediated by
clathrin-coated vesicles [11]. However, expression of L-arrest-
ins and its role in TSH receptor desensitization has not been
investigated in human thyroid tissues.
Somatic thyrotropin-receptor (TSHR) mutations cause a
constitutive activation of the TSHR leading to chronic stim-
ulation of the cAMP pathway in the majority of toxic thyroid
nodule (TTN)s [12^15]. Less frequently constitutively activat-
ing mutations in the GsK-protein gene are found in TTNs
[16,17]. Constitutive activation of the L2-adrenergic receptor
(L2-AR) by mutations induces constitutive desensitization and
downregulation of the receptor [18]. A similar desensitization
mechanism is very likely for constitutively activating TSH
receptor mutations.
The cAMP pathway is thought to be responsible for di¡er-
entiation, function and growth of thyroid follicular cells [19].
Therefore chronic stimulation of cAMP is likely to explain the
clinical phenotype characterized by hyperthyroidism and nod-
ule growth. Signi¢cantly higher thyroid hormone release in
TTNs than in the surrounding tissue has been reported [20].
The various TSH receptor mutations di¡er considerably in
their functional properties, determined in in vitro assays
[14,21]. However, no correlation with the phenotype could
be found for somatic [22] or germline [23] TSH receptor mu-
tations. Feedback mechanisms like L-arrestin-induced desensi-
tization and downregulation of the receptor are possible ex-
planations for the di¡erences found between TSH receptor
genotype and clinical phenotype.
We therefore asked the following questions: (l) Which L-
arrestins interact with the TSH receptor? (2) Which L-arrest-
ins are expressed in the human thyroid? (3) Does the expres-
sion pattern of L-arrestins in TTNs di¡er from normal sur-
rounding tissue or cold thyroid nodules (CTN)?
2. Materials and methods
2.1. Tissue samples
Thyroid nodules were characterized by ultrasound and scintiscan.
All TTNs showed increased technetium uptake with suppression of
the surrounding tissue. None CTNs took up technetium. All preop-
eratively identi¢ed nodules were also identi¢ed during surgery and by
histology. Somatic TSH receptor mutations in the hot nodules were
previously determined by DGGE and subsequent direct sequencing of
the positive bands [24]. The samples were stored in liquid nitrogen.
2.2. Membrane preparation
Frozen tissues were ground in liquid nitrogen, thawed and taken up
in membrane preparation bu¡er (40 mM Tris^HCl, 250 mM sucrose,
0.1 mM DTT, 0.1 mM PMSF, pH 7.4). The homogenates were ¢rst
centrifuged at 700Ug for 10 min at 4‡C. The supernatant was further
centrifuged at 60 000Ug for 45 min at 4‡C. The pellet (membrane
fraction) was resuspended in membrane preparation bu¡er. The
supernatant was used as cytosolic fraction. Protein concentrations
were determined by measuring the absorption at 280 nm.
2.3. Cell culture and transfection
HEK 293 cells were grown in Dulbecco’s modi¢ed Eagle’s medium
supplemented with 10% fetal bovine serum, 100 units/ml penicillin and
100 Wg/ml streptomycin (Gibco BRL, Karlsruhe, Germany) at 37‡C in
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a humidi¢ed 5% CO2 incubator. For cAMP assays, the cells were
transfected using the FuGENE 6 (Roche, Mannheim, Germany)
transfection reagent according to the manufacturer’s instructions. In
brief, 2U105 COS-7 cells per well were seeded into 12 well plates 24 h
before cotransfection with plasmid constructs (1 Wg DNA/well) con-
taining the coding sequence of the TSHR and L-arrestin 1, L-arrestin
2 or a dominant negative L-arrestin 1 mutant (V53D) or the TSHR
and the empty psvl-vector. The dominant negative L-arrestin 1 mutant
(V53D) was a generous gift from Dr. J. Benovic (Thomas Je¡erson
University). Functional assays were performed 48 h after transfection
and repeated two times.
2.4. Measurement of cAMP
For cAMP assays HEK 293 cells were washed in serum-free Dul-
becco’s modi¢ed Eagle’s medium, followed by preincubation with the
same medium containing 1 mM 3-isobutyl-1-methyl-xanthine (Sigma
Chemical Co., St. Louis, MO, USA) for 20 min at 37‡C in a humidi-
¢ed 5% CO2 incubator. Subsequently, cells were stimulated with
bTSH (10 mU/ml) for 1 h. Reactions were terminated by aspiration
of the medium and addition of 0.5 ml 0.1 N HCl. Supernatants were
collected and dried. The cAMP content of the cell extracts was deter-
mined with a commercial kit (Amersham Pharmacia Biotech,
Braunschweig, Germany) according to the manufacturer’s instruc-
tions.
2.5. Western blot analysis
The cytosolic and membrane fractions of all samples were heated at
95‡C for 5 min in sample bu¡er [25] and electrophoresed (100 Wg
protein/lane) on 10% polyacrylamide gels containing 0.1% SDS using
the discontinuous bu¡er system described by Davis [26]. Separated
proteins were electroblotted onto nitrocellulose membranes (Schleich-
er and Schuell, Dassel, Germany) using a semidry blotting system
(Bio-Rad, Hercules, CA, USA). The membranes were blocked with
5% non-fat dry milk in TBS/T (20 mM Tris^HCl, pH 7.6, 0.8% NaCl,
0.1% Tween 20) for 1 h at room temperature and probed overnight
with mouse anti-L-arrestin 1 or 2 antibody (Transduction Laborato-
ries, San Diego, CA, USA) (1:200 dilution) or anti-actin antibody
(Sigma Chemical Co., St. Louis, MO, USA) (1:500 dilution) at 4‡C
in TBS/T containing 5% BSA. After washing the membranes three
times for 5 min, they were incubated for 1 h at room temperature
with a horseradish peroxidase-conjugated anti-mouse antibody (New
England Biolabs, Beverly, MA, USA) diluted 1:3000 in blocking so-
lution. Following washing with TBS/T (4U5 min), membranes were
incubated with the chemiluminescence reagent (SuperSignal West
Pico, Pierce, Rockford, IL, USA) for 5 min at room temperature.
Immunoreactive proteins were detected with the ChemiImager 4000
(Alpha Innotech Corporation, San Leandro, USA) and quanti¢ed
using the Alpha Ease 4.0 software from Alpha Innotech Corporation.
The measurements were carried out in duplicates and repeated.
2.6. ELISA
98-Well plates were coated overnight at 4‡C with 0.5^2.0 Wg sample
protein per well diluted in 100 Wl coating bu¡er (15 mM Na2CO3, 0.35
m NaHCO3, 3 mM NaN3, 0.1 mM PMSF). After blocking of unspe-
ci¢c protein bindings (100 Wl/well TBS/T containing 5% non-fat dry
milk, pH 7.6) for 1 h at room temperature and three washes (5 min in
150 Wl TBS/T per well) the plates were incubated with a 1:250 dilution
of a L-arrestin 2 antibody (Transduction Laboratories, San Diego,
CA, USA) in TBS containing 0.05% Tween 20 (100 Wl/well) for
90 min at room temperature. Subsequently, plates were washed three
times with TBS/T and incubated for 1 h at room temperature in a
1:2500 dilution of a horseradish peroxidase-conjugated anti-mouse
antibody (New England Biolabs, Beverly, MA, USA) in TBS contain-
ing 0.05% Tween 20. After ¢nal washes in TBS/T (3U5 min, 150 Wl/
well), the reaction was developed using a substrate system containing
o-phenyldiamine (0.6 mg/ml) and H2O2 (30%, 0.5 Wl/ml) in phosphate-
citrate bu¡er (0.15 M, pH 5.0). The enzymatic reaction was stopped
after 30 min at 37‡C with 3 M HCl (100 Wl/well) and the samples were
measured at 492 nm using a microplatereader. All measurements were
carried out twice.
2.7. Data analysis
The distribution of L-arrestins was expressed as percent of the sum
of L-arrestins in nodular and in surrounding tissue, L-arrestin expres-
sion is given as means þ S.E.M. of duplicate measurements. cAMP
values of cotransfection experiments are given as means þ S.E.M. of
one representative experiment, carried out in duplicates. Statistical
analysis was carried out by Student’s t-test.
3. Results
Both, L-arrestin 1 as well as L-arrestin 2 were detectable by
Western blotting in all investigated thyroid tissues (Fig. 1).
For better quanti¢cation of L-arrestin 2 we designed a very
sensitive ELISA. The speci¢city of the L-arrestin 2 detection
in the ELISA was also tested by Western blot for some sam-
ples. The Western blot showed the same relations of L-arrestin
2 expression between nodular and surrounding tissue as the
ELISA (data not shown). For quanti¢cation of L-arrestin 1
we used Western blotting followed by chemiluminescence
imaging, because none of the available L-arrestin 1 antibodies
used in the ELISA was able to detect L-arrestin 1. All quan-
Fig. 1. Expression of L-arrestin 1 (55 kDa) and L-arrestin 2 (45
kDa) in normal thyroid tissue. The tissue homogenates were electro-
phoresed on SDS^polyacrylamide gels (100 Wg protein per lane),
transferred to nitrocellulose membranes and probed with monoclo-
nal mouse antibodies followed by HRP-linked second antibody and
chemiluminescence imaging.
Fig. 2. Mean distribution of L-arrestins in TTN. L-Arrestin 1 was
measured as duplicates in 12 TTNs and quanti¢ed by Western blot-
ting followed by chemiluminescence imaging. L-Arrestin 2 was mea-
sured as duplicates in 12 TTNs and quanti¢ed by ELISA.
(*P6 0.05, **P6 0.01, ***P6 0.001)
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ti¢cations of L-arrestins were reproducible. There were no
di¡erences in the actin expression between the nodular and
surrounding tissue samples (data not shown). As puri¢ed L-
arrestins are not commercially available the total amount of
L-arrestins could not be determined. The distribution of L-
arrestins was expressed as percent of the sum of L-arrestins
in nodular and in surrounding tissue. The sum of each L-
arrestin in nodular and in surrounding tissue represents 100%.
3.1. Expression of L-arrestins in TTNs
In the membrane fraction of 12 investigated TTNs we
found higher amounts (63.9 þ 2.3%; P6 0.001; Fig. 2) of L-
arrestin 2 in the TTNs than in the surrounding tissues. Except
for two of the 12 TTNs the di¡erences were signi¢cant for all
TTNs (Fig. 3B). In the cytosol of these TTNs we also found
higher amounts (67.6 þ 4.9%; P6 0.001; Fig. 2) of L-arrestin
2 in the nodules than in the surrounding tissues. Only two of
12 samples showed an inverse expression pattern for cytosolic
L-arrestin 2. The di¡erences were signi¢cant for all TTNs
(Fig. 3A). In contrast to the relatively homogeneous results
obtained for L-arrestin 2 there was a lower amount of L-ar-
restin 1 in the membrane fraction of six TTNs, no di¡erent L-
arrestin 1 expression in the membrane fraction of four TTNs
and a signi¢cantly higher L-arrestin 1 expression in the mem-
brane fraction of two TTNs (Fig. 4). The mean distribution of
L-arrestin 1 in the membrane fraction of all 12 investigated
TTNs showed a signi¢cantly decreased level (39.8 þ 4.9%;
P6 0.01; Fig. 2) compared to the surrounding tissue. The
L-arrestin 1 expression in the cytosol of 12 investigated
TTNs was not di¡erent from the surrounding tissue (Fig. 2).
3.2. Expression of L-arrestins in CTNs
In contrast to the homogeneous expression of L-arrestin 2
in TTNs there was no predominant expression pattern for
L-arrestins 1 or 2 in CTNs. In the cytosol of six out of
nine investigated CTNs we detected signi¢cantly lower
(35.0 þ 6.4%; P6 0.001; Fig. 5) amounts of L-arrestin 2 in
the nodules compared to the surrounding tissues whereas no
di¡erence was found in the cytosol of one CTN and an in-
verse pattern was observed in the cytosol of two CTNs (Fig.
6). The mean level of L-arrestin 2 in the membrane fraction of
Fig. 3. Distribution of cytosolic (A) and membrane-bound (B) L-ar-
restin 2 in TTNs quanti¢ed by ELISA. Data are given as means
þ S.E.M. of duplicate measurements (*P6 0.05, **P6 0.01,
***P6 0.001; boxed numbers: samples with TSH receptor muta-
tion).
Fig. 4. Distribution of membrane-bound L-arrestin 1 in TTN quan-
ti¢ed by Western blotting followed by chemiluminescence imaging.
Data are given as means þ S.E.M. of duplicate measurements
(*P6 0.05, **P6 0.01, ***P6 0.001; boxed numbers: samples with
TSH receptor mutation).
Fig. 5. Mean distribution of L-arrestins in CTN. L-Arrestin 1 was
measured as duplicates in nine CTNs and quanti¢ed by Western
blotting followed by chemiluminescence imaging. L-Arrestin 2 was
measured as duplicates in nine CTNs and quanti¢ed by ELISA
(*P6 0.05, **P6 0.01, ***P6 0.001).
Fig. 6. Distribution of cytosolic L-arrestin 2 in CTN quanti¢ed by
ELISA. Data are given as means þ S.E.M. of duplicate measure-
ments (*P6 0.05, **P6 0.01, ***P6 0.001).
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CTNs was not di¡erent from the surrounding tissue (Fig. 5).
Moreover, the mean L-arrestin 1 level in membranes or cyto-
sol of nine CTNs was not di¡erent from the surrounding
tissue (Fig. 5).
The expression data were compared to the thyroid size,
clonality and mutations of the TSH receptor of each sample,
but no coherence could be found (data not shown).
3.3. Cotransfection experiments
TSH stimulated (10 mU/ml, 1 h) cAMP accumulation in
HEK 293 cells, cotransfected with the TSH receptor and L-
arrestin 1 or 2 was signi¢cantly decreased to 37.2% þ 6.4
(P6 0.05) for L-arrestin 1 and to 33.9 þ 7.5% (P6 0.05) for
L-arrestin 2 compared to HEK 293 cells transfected only with
the TSH receptor (100%) (Fig. 7). cAMP was unchanged after
TSH stimulation in COS 7 cells cotransfected with the TSH
receptor and a dominant negative L-arrestin 1 mutant (V53D)
compared to COS 7 cells transfected only with the TSH re-
ceptor. All cotransfection experiments were reproducible.
4. Discussion
Up to now the role of L-arrestins for the signaling of the
human TSH receptor in thyroid tissue has not been investi-
gated. L-arrestin 1 and 2 are the known members of the L-
arrestin family and are expressed in a broad range of human
tissues. In this study we found L-arrestin 1 and 2 expression in
human thyroid tissue. Expression of L-arrestin 1 but not L-
arrestin 2 in FRTL 5 cells has recently been reported [9,10]. In
addition a thyroid speci¢c L-arrestin 2 cDNA with a high
homology to L-arrestin 2 has been cloned [27]. However, the
functional impact of the L-arrestin expression in human thy-
roid tissue remains to be clari¢ed. The desensitizing e¡ect of
L-arrestins on G protein-coupled receptor signaling has been
demonstrated in many studies [28^34]. Overexpression of L-
arrestin 1 in stably transfected Chinese hamster ovary cell
lines enhanced the desensitization of L2-AR [33]. Moreover,
a partially puri¢ed preparation of L-arrestin 1 inhibited the
ability of L-adrenergic receptor kinase (L-ARK)-phosphory-
lated L2-AR to activate Gs by s 75% [3], indicating that L-
arrestin 1 works in concert with L-ARK to induce agonist
speci¢c desensitization of the L2-AR. Furthermore, L-arrestin
binding to L2-AR not only terminates receptor-G protein cou-
pling followed by a decrease of cAMP. It also initiates a
second wave of signal transduction in which the desensitized
receptor acts as a structural component of a mitogenic signal-
ing complex [6].
TSH stimulation of FRTL 5 cells increased the level of
cytosolic L-arrestin 1 and, in turn, the elevated levels of L-
arrestin 1 attenuated TSH-induced cAMP accumulation and
increased TSH receptor desensitization [9]. In contrast Na-
gayama et al. [10] failed to demonstrate a TSH dependent
mechanism of L-arrestin 1 regulation in FRTL 5 cells.
Evidence for a functional importance of L-arrestins for
TSH receptor signaling is also implied by experiments with
the lutropin/choriogonadotropin receptor which displays a
high homology to the TSH receptor. The desensitization of
lutropin/choriogonadotropin receptor-stimulated adenylyl cy-
clase activity in porcine ovarian follicular membranes is medi-
ated by L-arrestin 1 [30]. Furthermore, cotransfection of hu-
man kidney 293 cells with the lutropin/choriogonadotropin
receptor and GRK2 or L-arrestin 1 or L-arrestin 2 enhances
internalization and increases downregulation of the receptor
[28,32]. Moreover, the folitropin receptor in human kidney
293 cells [29,31] and in mouse Ltk cells [34] shows enhanced
agonist-induced internalization after cotransfection with L-ar-
restin 1 or 2.
Overexpression of L-arrestin 1 in COS 7 cells or in FRTL 5
cells decreased TSH receptor dependent cAMP production
[9,10] probably by an increased desensitization of the TSH
receptor.
We found that both L-arrestins are able to desensitize the
TSH receptor in vitro in a coexpression system in HEK 293
cells (Fig. 7). In contrast no decrease of TSH-stimulated
cAMP could be detected in HEK 293 cells cotransfected
with the TSH receptor and a dominant negative L-arrestin 1
mutant compared to HEK 293 cells transfected only with the
TSH receptor. Our results con¢rm previous data indicating a
L-arrestin 1 dependent desensitization mechanism for the TSH
receptor [9,10] and extend the possibilities for TSH receptor
desensitization to L-arrestin 2.
The cytosol contains free L-arrestin and the membrane frac-
tion receptor-bound L-arrestin [6,35]. The amount of free (cy-
tosolic) L-arrestin re£ects the entire L-arrestin pool [7]. The
TSH receptor is desensitized by L-arrestin binding [9]. There-
fore, the amount of receptor-bound L-arrestin which is found
in the membrane fraction re£ects the L-arrestin fraction which
is involved in receptor desensitization (inactivation). There-
fore, we separated the cytosolic and the membrane fraction
for each sample.
Based on the previous ¢ndings in FRTL 5 cells [9] we ex-
pected an increased expression of L-arrestin 1 in TTNs with
mutation-induced TSH receptor activation. However, un-
changed levels of L-arrestin 1 in the cytosol of TTNs (Fig.
2) and decreased levels of L-arrestin 1 in the membrane frac-
tion of TTNs compared to the normal surrounding tissue were
detected (Figs. 2 and 4). These ¢ndings most likely indicate an
unchanged total pool of L-arrestin 1 whereas the internaliza-
tion and degradation of the L-arrestin 1-TSH receptor com-
Fig. 7. Basal and TSH-stimulated (10 mU/ml, 1 h) cAMP accumula-
tion in HEK 293 cells cotransfected with the TSH receptor and L-
arrestin constructs. Data are given as means þ S.E.M. of one repre-
sentative experiment, carried out in duplicate.
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plex seems to be increased. This assumption is supported by
the signi¢cant decrease of cAMP accumulation in TSH-stimu-
lated HEK 293 cells cotransfected with the TSH receptor and
L-arrestin 1. Similar results have been reported for constitu-
tively activating rhodopsin mutants [36]. The phosphorylation
of these constitutively activating rhodopsin mutants by rho-
dopsin kinase and the subsequent arrestin binding apparently
led to sequestration of the entire arrestin pool.
Higher levels of L-arrestin 2 in the membrane fraction of all
screened TTNs compared to the surrounding tissue (Figs. 2
and 3b) together with increased expression of L-arrestin 2 in
the cytosol of 10 out of 12 screened TTNs compared to the
surrounding tissue (Figs. 2 and 3a) suggest a increased TSH
receptor desensitization by L-arrestin 2 in these toxic nodules.
Chronic stimulation of the cAMP-pathway is very likely in
TTNs, especially those with constitutively activating TSH re-
ceptor mutations. Therefore, the increased L-arrestin 2 expres-
sion in the toxic nodules is most likely induced by the consti-
tutive activation of the cAMP pathway. As the cAMP
production in the thyroid is mainly induced by the TSH re-
ceptor, L-arrestin 2 is most likely part of a feedback mecha-
nism which desensitizes the TSH receptor. The higher levels of
L-arrestin 2 compared to L-arrestin 1 in the membrane frac-
tion of TTNs are most likely due to the predominant role of
L-arrestin 2 in TSH receptor desensitization.
The L-arrestin 1 level in the cytosol and the membrane
fraction of CTNs was not di¡erent from the normal surround-
ing tissue (Fig. 5) most likely indicating a normal L-arrestin 1
expression and TSH receptor desensitization in these nodules
and the surrounding tissue. Moreover, we found a decreased
expression of L-arrestin 2 in the cytosol of CTNs (Figs. 5 and
6) compared to the surrounding tissue. Unchanged levels of L-
arrestin 2 in membrane fractions of CTNs (Fig. 5) compared
to surrounding tissues indicate an equal desensitization of the
TSH receptor in cold nodules and corresponding surrounding
tissues by L-arrestin 2. As the cAMP-pathway is most likely
not constitutively activated in CTNs in contrast to TTNs the
decreased L-arrestin 2 in the cytosol of CTNs further supports
the hypothesis that the main signaling pathways in cold and
TTNs are di¡erent. In addition, the feedback mechanism
which desensitizes the TSH receptor is apparently not acti-
vated in CTNs.
In summary, our ¢ndings demonstrate the expression of
both, L-arrestin 1 and 2 in the human thyroid. In vitro both
L-arrestins are capable to interact with the TSH receptor and
to desensitize the receptor after stimulation. However, in hot
nodules L-arrestin 2 seems to be the predominant cAMP de-
pendent regulator of the TSH receptor activity.
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